Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 19/20 | 0.64 |
| ▸ | JAK2 | O60674 | 14/20 | 0.64 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466945 | 0.92 | JAK1 (0.65) | JAK1JAK2 | |
| SCHEMBL24474748 | 0.91 | JAK1 (0.67) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL29431073 | 0.91 | JAK1 (0.67) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL25369813 | 0.91 | JAK1 (0.64) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL25370213 | 0.90 | JAK1 (0.64) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL24474969 | 0.87 | JAK1 (0.68) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL24474769 | 0.87 | JAK1 (0.66) | JAK1JAK2 | |
| SCHEMBL24474853 | 0.86 | JAK1 (0.65) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL26078109 | 0.86 | JAK1 (0.67) | JAK1JAK2JAK3KCNH2 | |
| SCHEMBL18662624 | 0.84 | JAK1 (0.62) | JAK1JAK2JAK3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319670-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| EP-3353168-B1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| EP-4219482-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-08-02 | — | — | EP | disclosed |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319670-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | JAK1 3/4885JAK2 1/4885JAK3 2/4885 |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | JAK1 3/4885JAK2 1/4885JAK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.